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Abstract
Background: Fluoropyrimidines such as 5-fluorouracil (5-FU) and 5-fluoro-2'deoxyuridine
(FUDR) are among the most effective chemotherapeutic agents for treatment of metastatic
colorectal cancer (CRC). Increased expression of thymidylate synthetase (TS) in CRC metastases
has been proposed to be an important mechanism of resistance to fluoropyrimidine-based
chemotherapy.
Methods: The present study investigated whether TS mRNA levels in liver metastases of 20 CRC
patients before treatment with FUDR by hepatic arterial infusion (HAI) correlated with frequency
of clinical response or survival duration.
Results: Median survival duration of patients with TS mRNA levels above and below the median
was 15 and 18 months, respectively (p > 0.05). Clinical response was achieved in 40% of patients
with low TS mRNA levels, but in only 20% of patients with high TS mRNA levels (p = 0.01). TS
mRNA levels were also measured for liver metastases of 7 of the patients that did not achieve a
clinical response. A statistically significant increase in expression of TS mRNA was observed for
liver metastases resistant to chemotherapy (21 ± 14) in comparison to liver metastases of the same
patients before chemotherapy (8 ± 4) (p = 0.03).
Conclusion: This is the first report to demonstrate increased TS expression in liver metastases
from CRC patients resistant to fluoropyrimidine based chemotherapy. These findings are
consistent with previous studies indicating that increased TS expression is associated with
resistance to fluoropyrimidine-based chemotherapy.
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Colorectal cancer (CRC) occurs commonly in both men
and women of developed nations [1]. There is a high risk
of distant metastasis and local recurrence of CRC. Signifi-
cant advances have been made in surgical management
and adjuvant treatment of CRC patients. Adjuvant CRC
therapies include local radiation and systemic chemother-
apy that may be administered either preoperatively or
postoperatively [2]. Despite these developments in treat-
ment, nearly half of CRC patients will die from this
disease.
Fluoropyrimidines such as 5-fluorouracil (5-FU) and 5-
fluoro-2'-deoxyuridine (FUDR) are among the most effec-
tive chemotherapeutic agents for treatment of CRC.
Hepatic arterial infusion (HAI) of FUDR yields a complete
or partial response in approximately 40% of CRC patients
with liver metastasis [3]. Fluoropyrimidine metabolites
form a covalent complex with thymidylate synthetase
(TS). Formation of this complex prevents biosynthesis of
intracellular thymidylate, which is essential for DNA bio-
synthesis. An increase in TS protein levels has been sug-
gested to be an important mechanism of resistance to
chemotherapy with fluoropyrimidines [4].
Several studies have demonstrated that TS mRNA and pro-
tein levels of CRC metastases frequently vary among dif-
ferent anatomical sites of metastasis and are often
significantly different from that of the primary tumor. For
example, TS protein levels were higher in abdominal CRC
metastases than in hepatic CRC metastases. The variation
of TS expression in CRC metastases in comparison to the
primary tumor supports the argument that TS expression
in primary CRC tumors is not predictive of chemothera-
peutic response in CRC patients with metastatic disease
[5].
The stage of disease is usually the primary factor dictating
whether a CRC patient receives chemotherapy. However,
it would be useful to identify factors that may predict
treatment response to optimize clinical management of
CRC. The aim of the present study was to determine
whether response of hepatic CRC metastases to FUDR
administered by HAI is correlated with TS mRNA levels in
liver metastases of CRC patients prior to chemotherapy.
TS mRNA levels in liver metastases were also examined
after treatment in CRC patients that did not respond to
chemotherapy to test the hypothesis that liver metastases
resistant to FUDR exhibited increased TS mRNA levels.
Methods
Patients
This study included 20 CRC patients administered HAI
therapy for nonresectable liver metastases at the Centro di
Riferimento Oncologico (CRO), National Cancer Insti-
tute, Aviano. Patients included in the study gave informed
consent and the Hospital Ethical Committee approved of
the study. The Vital-Port Vascular Access System (Baxter,
Italy) was used to administer FUDR (Roche, NJ, USA) by
HAI at a dose of 0.2 mg/kg per day for 14 days every 28
days. Treatment cycles continued until progressive disease
(PD) was detected. Abdominal computerized axial tom-
ography (CAT) was utilized during treatment and for
monthly evaluation of treatment response. Complete
response (CR) was defined as a clinical and radiographic
disappearance of liver metastases. Partial response (PR)
corresponded to a reduction in metastasis volume by
more than 50% and stable disease (SD) corresponded to
a reduction in metastasis volume by 50% or less. An
increase in metastasis volume by more than 25% or
appearance of a new metastasis indicated PD.
Tumor biopsy collection
Tumor biopsy specimens, collected before chemotherapy,
were removed during laparotomy for implantation of the
intra-arterial infusion device without substantially
expanding the scope of surgery. Tumor biopsy specimens,
collected after chemotherapy, were removed from
patients with PD or SD by hepatic arterial cannulation of
liver metastases identified by CAT after two cycles of
chemotherapy. Specimens were frozen in liquid nitrogen
immediately after collection and stored at -80°C. All
patients provided written consent prior to collection of
tumor biopsy specimens.
TS mRNA quantitation
The procedure used to quantitate TS mRNA has been
described previously [6,7]. RNA isolated from tumor
biopsy specimens was used as a template for cDNA syn-
thesis. TS and β-actin cDNA fragments were amplified
separately by polymerase chain reaction (PCR). The 5' end
of forward primers used for cDNA amplification included
a T7 RNA polymerase promoter site. T7 RNA polymerase
and α-32P-CTP were used for synthesis of labeled cRNA
from amplified cDNA fragments. Transcription products
were subjected to electrophoresis with an 8% denaturing
polyarcrylamide gel then visualized by autoradiography.
Bands corresponding to TS and β-actin cRNAs were iso-
lated then quantified with a liquid scintillation counter.
PCR was conducted with various starting concentrations
of cDNA to determine the range for which the amount of
cDNA template used was linearly related to the amount of
cRNA product obtained. TS mRNA levels were calculated
from the ratio of the slope of the linear portion of the TS
curve to that of β-actin and are expressed in arbitrary units
(AU).
Data analysis
Patients were grouped either by TS mRNA level or clinical
outcome of chemotherapy. Clinical response toPage 2 of 6
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clinical response corresponded to patients with either SD
or PD. SAS software was used for data analysis [8]. Sur-
vival duration was defined as the interval of time between
date of treatment initiation and date of death or last con-
tact. Survival curves were plotted by the Kaplan and Meier
method [9]. Univariate analysis of survival duration was
performed to calculate Cox proportional hazard ratios
(HRs) and corresponding 95% confidence intervals (CIs)
[10]. The mean TS mRNA level of patients responding to
chemotherapy was compared with that of patients that
did not respond to chemotherapy. In some patients that
did not respond to chemotherapy, mean TS mRNA levels
before and after treatment were compared. Differences
between means were performed by a non-parametric test
(Wilcoxon test) [11]. The mean TS mRNA level for each
group is presented together with its corresponding stand-
ard deviation. Differences in survival duration, frequency
of clinical response, HR, and TS mRNA level, were defined
to be statistically significant if the p value was less than
0.05 by a two-sided test.
Results
Clinical characteristics of the 20 patients studied are indi-
cated in Table 1. The median age was 59 years and ranged
from 44 to 79 years. Response to chemotherapy was
observed in 6 patients. CR was achieved in 1 patient and
PR was achieved in 5 patients. SD remained in 5 patients
and PD occurred in 9 patients (Table 1). The median sur-
vival duration for all patients was 17 months and ranged
from 4 to 81 months. The median TS mRNA level for all
patients was 13 and ranged from 4 to 32. Survival dura-
tion of patients with TS mRNA levels above and below the
median is plotted by the Kaplan and Meier method in
Figure 1.
Median survival duration of patients with a TS mRNA
level below the median was 18 months and ranged from
4 to 81 months. Median survival duration of patients with
a TS mRNA level above the median was 15 months and
ranged from 5 to 34 months. The difference in survival
duration between patients with TS mRNA levels above
and below the median was not statistically significant.
However, a statistically significant difference in frequency
Table 1: Clinical characteristics of CRC patients with nonresectable liver metastases.






1 50/F PD 4 4 11
2 70/M PD 20 4 12
3 69/F PD 17 5 21
4 61/M PD 20 12 34
5 44/F PD 27 15 47
6 53/M PD 5 10 9
7 56/F PD 9 23 ND
8 58/M PD 7 14 ND
9 60/F PD 13 15 ND
10 52/M SD 11 9 14
11 79/M SD 25 17 ND
12 49/F SD 34 32 ND
13 63/M SD 8 20 ND
14 56/F SD 5 19 ND
15 51/F PR 17 20 ND
16 65/M PR 21 6 ND
17 55/M PR 17 8 ND
18 70/M PR 28 15 ND
19 73/F PR 81 8 ND
20 65/M CR 47 8 ND
* This value is expressed in arbitrary units; F, female; M, male; PD, progression disease; SD, stable disease; PR, partial response; CR, complete 
response; ND, not determined.
Table 2: Clinical response rate of patients stratified by TS mRNA 
level.
TS mRNA level Clinical response rate*
<13 4/10, 40%
>13 2/10, 20%
p value p = 0.01
*Clinical response is defined as CR or PR.Page 3 of 6
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TS mRNA level above and below the median (Table 2).
Clinical response was achieved in 40% of patients with a
TS mRNA level below the median, but in only 20% of
patients with a TS mRNA level above the median (p =
0.01).
Table 3 summarizes results of a univariate analysis of
patients stratified by chemotherapeutic response and TS
mRNA level. The HR for death was 3.31 for patients not
responding to chemotherapy in comparison to patients
that did respond to chemotherapy (p < 0.05). The HR for
death was 1.34 for patients with a TS mRNA level above
the median in comparison to patients with a TS mRNA
level below the median. The difference in HR for death
between patients with TS mRNA levels above and below
the median was not statistically significant.
Patients that responded to chemotherapy had a mean TS
mRNA level of 11 ± 5 AU before receiving therapy.
Patients who did not respond to chemotherapy had a
mean TS mRNA level of 14 ± 8 AU before treatment,
which was slightly higher than that of patients that did
respond to treatment. However, such differences were not
statistically significant (p = 0.42). TS mRNA levels of liver
metastases that remained after chemotherapy were also
measured for 7 of the 14 patients that did not achieve a
clinical response to chemotherapy. Liver metastases iso-
lated from these patients exhibited a statistically signifi-
cant increase in mean TS mRNA level in comparison to
liver metastases isolated from the same patients before
chemotherapy. The mean TS mRNA level of these patients
increased from 8 ± 4 AU before chemotherapy to 21 ± 14
AU after treatment (p = 0.03) (Figure 2).
Survival probability of 20 patients with colorectal liver metas-tasis by TS mRNA levelsFigure 1
Survival probability of 20 patients with colorectal liver metas-
tasis by TS mRNA levels. Solid line, TS mRNA ≤ 13; broken 
line, TS mRNA > 13 TS mRNA levels in patients with colorectal liver metastasis before and aft r treatm t ith HAI ther py with FUDRFigure 2
TS mRNA levels in patients with colorectal liver metastasis 
before and after treatment with HAI therapy with FUDR
Table 3: Univariate survival analysis of 20 CRC patients with liver metastases stratified by TS mRNA level and clinical response.
Univariate analysis*
N (%) HR 95% CI
Response
CR + PR 6 (30) 1†
SD + PD 14 (70) 3.31 (1.06–10.32)
Chi-square; p value χ2 = 4.24; p = 0.04
TS mRNA level
<13 10 (50) 1†
>13 10 (50) 1.34 (0.52–3.44)
Chi-square; p value χ2 = 0.48; p = 0.54
*Cox proportional hazard ratio (HR) and corresponding 95% confidence interval (CI). †Reference value.Page 4 of 6
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Several prognostic factors have been identified in recent
years that correlate with progression of hepatic metastatic
disease in patients with CRC [12,13]. These factors
include primary tumor size as well as number and size of
metastases. Several approaches have been suggested to
optimize chemotherapeutic treatment of CRC patients
with liver metastases. One approach is to test in vitro
chemosensitivity of primary tumor cells to determine
which regimens the tumor cells are most sensitive to.
Additionally, pharmacogenetic markers may be analyzed
to facilitate selection of chemotherapeutic agents [14].
Both preclinical and clinical data have suggested that TS
expression may be useful for predicting clinical response
of metastatic CRC patients to fluoropyrimidine based
chemotherapy [15-17]. Several in vitro studies have dem-
onstrated an increased level of TS expression in tumor
cells resistant to fluoropyrimidines [18]. Kornmann et al.
reported that TS mRNA expression is a predictive marker
of response to HAI therapy based on FUDR [16]. How-
ever, TS mRNA levels of liver CRC metastases resistant to
fluoropyrimidine-based chemotherapy have not been
previously compared to levels present before
chemotherapy.
In the present study, a statistically significant increase in
TS mRNA levels was observed in liver metastases from
CRC patients resistant to FUDR chemotherapy in compar-
ison to liver metastases from the same patients before
chemotherapy (p = 0.03) (Figure 2). In addition, we
observed that patients with a low TS mRNA level before
chemotherapy achieved a clinical response more fre-
quently (40%) than patients with a high TS mRNA level
before chemotherapy (20%). This difference in frequency
of clinical response was statistically significant (p = 0.01).
These findings support a role for increased TS expression
as a mechanism of resistance to fluoropyrimidine based
chemotherapy.
These results are consistent with previous studies demon-
strating that low TS expression predicted significantly
longer survival of gastric [19] and colon cancer patients
receiving fluoropyrimidine based chemotherapy [17,20].
Recently, Gonen et al [13] reported that TS expression in
liver metastases from CRC patients predicted survival
duration and extent of disease progression. Conversely,
Paradiso et al [21] did not find any significant association
between TS expression level and survival duration. CRC
patients in the present study with a low TS mRNA level did
have a slightly longer median survival duration than those
with a high TS mRNA level. However, this difference was
not statistically significant.
Although the number of patients studied is relatively
small, the results of the present study support a role for
increased TS expression as a mechanism of resistance to
fluoropyrimidine based chemotherapy. The CRC patients
resistant to chemotherapy in which TS mRNA levels were
increased in liver metastases after chemotherapy demon-
strate this relationship in particular. These findings sug-
gest that it may be useful to consider intratumoral TS
expression during choice of therapy for patients with
advanced colon cancer. Significant improvements in treat-
ment of CRC patients may be possible by individualizing





ML, PMN, and S Travali participated in the experimental
and molecular analyses. ML and PMN also participated in
the interpretation of results and drafted the manuscript.
RT performed statistical analysis. EC, FS, and SM partici-
pated in the processing and storage of biological samples.
S Tumolo and GT carried out the recruitment of eligible
patients. GT conceived of the study and conducted the
interpretation of results. MB participated in the study
design and coordination. All authors read and approved
the final manuscript.
Acknowledgements
The authors thank Mrs Luigina Mei for editorial assistance. This work was 
partially supported by Ricera Finalizzata 2001, Ministrero della Salute, Italy, 
Contract no.119
References
1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics, 1998.
CA Cancer J Clin 1998, 48:6-29.
2. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart
RW, Kubista TP, Poon MA, Meyers WC, Maillard JA, Twito DI, Mor-
ton RF, Veeder MH, Witzig TE, Cha S, Vidyarthi SC: Effective sur-
gical adjuvant therapy for high-risk rectal carcinoma. N Engl J
Med 1991, 324:709-715.
3. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J: Quality
of life and survival with continuous hepatic-artery floxuridine
infusion for colorectal liver metastases. Lancet 1994,
344:1255-1260.
4. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S,
Pinedo HM: Thymidylate synthase inhibition after administra-
tion of fluorouracil with or without leucovorin in colon can-
cer patients: implications for treatment with fluorouracil. J
Clin Oncol 1994, 12:2035-2042.
5. Marsh S, McKay JA, Curran S, Murray GI, Cassidy J, McLeod HL: Pri-
mary colorectal tumour is not an accurate predictor of
thymidylate synthase in lymph node metastasis. Oncol Rep
2002, 9:231-234.
6. Horikoshi T, Danenberg KD, Stadlbauer THW, Volkenandt M, Shea
LLC, Aigner K, Gustavsson B, Leichman L, Frösing R, Ray M, Gibson
NW, Spears CP, Danenberg PV: Quantitation of thymidylate
synthase, dihydrofolate reductase, and DT-diaphorase gene
expression in human tumors using the polymerase chain
reaction. Cancer Res 1992, 52:108-116.
7. Lenz H-J, Hill C, Danenberg KD, Leichman LL, Priest DG, Danenberg
PV: Rapid quantitative PCR for determination of relativePage 5 of 6
(page number not for citation purposes)
BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/11Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
gene expressions in tissue specimens. PCR Methods Appl 1995,
4:305-309.
8. SAS Institute Inc: "Sas User Guide: Language Version 8.1".
Cary, NC: SAS; 2000. 
9. Kaplan EL, Meier P: Nonparametric estimation from incom-
plete observations. J Am Stat Assoc 1958, 53:457-481.
10. Cox DR: Regression models and life tables. J R Stat Soc B 1972,
34:187-220.
11. Armitage P, Berry G: Statistical Methods in Medical Research.
Oxford: Blackwell Scientific Publication; 1985. 
12. Nanni O, Volpi A, Frassineti GL, De Paola F, Granato AM, Dubini A,
Zoli W, Scarpi E, Turci D, Oliverio G, Gambi A, Amadori D: Role of
biological markers in the clinical outcome of colon cancer. Br
J Cancer 2002, 87:868-875.
13. Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee
D, Klimstra D, Cordon-Cardo C, Bertino J, Kemeny N: Thymi-
dylate synthase expression in hepatic tumors is a predictor
of survival and progression in patients with resecable meta-
static colorectal cancer. J Clin Oncol 2003, 21:406-412.
14. Toffoli G, Gafa R, Russo A, Lanza G, Dolcetti R, Sartor F, Libra M, Viel
A, Boiocchi M: Methylenetetrahydrofolate reductase 677 C--
>T polymorphism and risk of proximal colon cancer in north
Italy. Clin Cancer Res 2003, 9:743-748.
15. Link KH, Kornmann M, Butzer U, Leder G, Sunelaitis E, Pillasch J,
Salonga D, Danenberg KD, Danenberg PV, Beger HG: Thymidylate
synthase quantitation and in vitro chemosensitivity testing
predicts responses and survival of patients with isolated non-
resectable liver tumors receiving hepatic arterial infusion
chemotherapy. Cancer 2000, 89:288-296.
16. Kornmann M, Link KH, Lenz HJ, Pillasch J, Metzger R, Butzer U, Leder
GH, Weindel M, Safi F, Danenberg KD, Beger HG, Danenberg PV:
Thymidylate synthase is a predictor for response and resist-
ance in hepatic artery infusion chemotherapy. Cancer Lett
1997, 18:29-35.
17. Aschele C, Lonardi S, Monfardini S: Thymidylate synthase
expression as a predictor of clinical response to fluoropyri-
midine-based chemotherapy in advanced colorectal cancer.
Cancer Treat Rev 2002, 28:27-47.
18. Peters GJ, Backus HH, Freemantle S, van Tirest B, Codacci-Pisanelli
G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod
HL, Bloemena E, Jeijer S, Jansen G, van Groeningen CJ, Pinedo HM:
Induction of thymidylate synthase as a 5-fluorouracil resist-
ant mechanism. Biochim Biophys Acta 2002, 1587:194-205.
19. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S,
Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J,
Leichman L: Thymidylate synthase mRNA level in adenocarci-
noma of the stomach: a predictor for primary tumor
response and overall survival. J Clin Oncol 1996, 14:176-182.
20. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B:
Increased thymidylate synthase gene expression in liver
metastases from colorectal carcinoma: implications for
chemotherapeutic options and survival. Cancer J Sci Am 1999,
5:34-40.
21. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero
A, Machiavelli M, De Lena M, Allegra CJ, Johnston PG: Thymidilate
synthase and p53 primary tumour expression as predictive
factors for advanced colorectal cancer patients. Br J Cancer
2000, 82:560-567.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/4/11/prepubPage 6 of 6
(page number not for citation purposes)
